Xencor (NASDAQ:XNCR) SVP Celia Eckert Sells 1,767 Shares

Xencor, Inc. (NASDAQ:XNCR) SVP Celia Eckert sold 1,767 shares of the stock in a transaction on Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $19,472.34. Following the sale, the senior vice president owned 76,918 shares in the company, valued at $847,636.36. The trade was a 2.25% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Celia Eckert also recently made the following trade(s):

• On Thursday, March 5th, Celia Eckert sold 3,244 shares of Xencor stock. The shares were sold at an average price of $11.25, for a total value of $36,495.00.
• On Tuesday, March 3rd, Celia Eckert sold 1,492 shares of Xencor stock. The shares were sold at an average price of $11.90, for a total value of $17,754.80.

Xencor Stock Up 4.9%

Shares of NASDAQ XNCR opened at $11.87 on Tuesday. Xencor, Inc. has a 12-month low of $6.92 and a 12-month high of $18.69. The firm’s 50-day simple moving average is $12.73 and its 200 day simple moving average is $13.03. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The company has a market cap of $870.55 million, a price-to-earnings ratio of -9.57 and a beta of 0.95.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.64) by $0.55. Xencor had a negative net margin of 73.20% and a negative return on equity of 14.58%. The firm had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same quarter last year, the company posted ($0.62) EPS. The company’s quarterly revenue was down 46.6% compared to the same quarter last year. On average, research analysts expect that Xencor, Inc. will post -3.68 earnings per share for the current fiscal year.

Xencor News Summary

Here are the key news stories impacting Xencor this week:

• Negative Sentiment: Xencor and Genentech have agreed to end their protein-therapeutics collaboration. This removes a strategic partner that could have provided development resources, milestone and/or royalty payments tied to the collaboration and could delay or change the path-to-market for affected programs; however, termination may return rights to Xencor and let the company seek new partners or advance programs independently. Xencor, Genentech to End Protein Therapeutics Collaboration
• Negative Sentiment: Multiple insider sales by senior Xencor executives were disclosed this week: CEO Bassil Dahiyat sold 14,870 shares on March 5 and 6,606 shares on March 6 (total 21,476 shares), SVP Celia Eckert sold 5,011 shares across March 5–6, and VP John Desjarlais sold 6,620 shares across March 5–6. Aggregate proceeds reported are in the low six-figure range per trade. These clustered sales by top executives can be read negatively by the market (profit-taking or reduced insider conviction), unless part of pre-planned 10b5‑1 arrangements (no such plan was disclosed in these notices). Relevant SEC filings: CEO Form 4(s) SVP Form 4(s) VP Form 4(s)

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on XNCR shares. Truist Financial started coverage on shares of Xencor in a report on Monday, November 24th. They issued a “buy” rating and a $29.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xencor in a research report on Monday, December 29th. Wall Street Zen cut Xencor from a “hold” rating to a “sell” rating in a research note on Saturday, February 28th. Finally, Barclays upped their price target on Xencor from $26.00 to $27.00 and gave the company an “overweight” rating in a research note on Thursday, February 26th. Eight equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xencor presently has a consensus rating of “Moderate Buy” and an average target price of $25.00.

Institutional Investors Weigh In On Xencor

A number of institutional investors and hedge funds have recently modified their holdings of XNCR. Hantz Financial Services Inc. lifted its holdings in Xencor by 209.1% in the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock valued at $37,000 after buying an additional 2,156 shares during the period. GAMMA Investing LLC grew its holdings in Xencor by 77.1% during the 3rd quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares during the period. Farther Finance Advisors LLC bought a new stake in shares of Xencor during the 3rd quarter valued at $44,000. Tower Research Capital LLC TRC raised its position in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 3,018 shares during the last quarter. Finally, Federated Hermes Inc. lifted its stake in shares of Xencor by 114.3% in the 3rd quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock valued at $46,000 after purchasing an additional 2,105 shares during the period.

Xencor Company Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.